Group 1 - The pharmaceutical commercial sector experienced a decline at the beginning of trading, with notable drops in stock prices [1] - Shuyupingmin saw a decrease of over 15%, while Renmintongtai fell by more than 7% [1] - Other companies such as Huaren Health, Dajia Weikang, and Ruikang Pharmaceutical also followed the downward trend [1]

【深圳商报讯】（记者 詹钰叶）在年报审计启动前夕，瑞康医药（002589）紧急更换会计师事务所， 此前携手共进两年的中兴财光华会计师事务所出局，这引发市场对其真实动机的质疑。双方均有"前 科"：前者最近5年内数次因违规被监管警示，后者正被证监会立案调查。 瑞康医药12月24日晚突发公告，宣布终止与中兴财光华会计师事务所的合作，改聘深圳久安承接2025年 度审计业务。而按惯例，A股公司的年报审计基本于次年1月启动、4月底前完成。对于变更理由，公司 在公告中提到"综合考虑公司业务发展及审计工作需求"。 市场猜测此举或为规避审计风险，互动平台也有不少投资者追问"为何偏偏在审计启动前更换？""是否 因中兴财光华被立案影响审计独立性？" 最近5年，瑞康医药多次因违规被警示。 这场"解约潮"的起因是中兴财光华会计师事务所卷入了ST立方财务造假案。 ...

Core Viewpoint - Ruikang Pharmaceutical has terminated its cooperation with Zhongxing Caiguanghua Accounting Firm and appointed Shenzhen Jiuan to undertake the 2025 audit, raising concerns about potential audit risks and independence issues [3][4]. Group 1: Company Actions - The company announced the change in auditors on December 24, citing "comprehensive consideration of business development and audit needs" without providing further details [3]. - The decision to change auditors comes just before the annual audit process, which typically starts in January and concludes by the end of April [3]. Group 2: Regulatory Issues - Ruikang Pharmaceutical has faced multiple regulatory warnings over the past five years, including a warning from the Shandong Securities Regulatory Bureau in December 2023 for serious violations [3]. - Specific violations include failing to disclose a 4.6 billion yuan related party transaction and not timely reporting litigation matters totaling 5.84 billion yuan [3]. Group 3: Management Turmoil - In July 2023, the company experienced significant management changes, including the detention of a board member and the resignation of the actual controller's son [4]. - These management upheavals coincide with a decline in the company's operational performance [4]. Group 4: Financial Performance - Revenue for Ruikang Pharmaceutical has seen significant declines from 2020 to 2024, with year-on-year decreases of 22.84%, 22.67%, 41.54%, 34.74%, and a slight drop of 0.85% in 2025 [4]. - The net profit for the company has also deteriorated, with a 63% year-on-year decline in the first three quarters of 2025 [4]. Group 5: Industry Context - Ruikang Pharmaceutical is not alone in terminating its relationship with Zhongxing Caiguanghua; at least 30 other A-share companies have also ended their partnerships with the firm amid concerns over its audit practices [5][6]. - The wave of terminations is linked to Zhongxing Caiguanghua's involvement in a financial fraud case, which has led to regulatory scrutiny and investigations [6].

证券代码：002589 证券简称：瑞康医药 公告编号：2025-058 瑞康医药集团股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、会议召开的基本情况 瑞康医药集团股份有限公司（以下简称"公司"）第五届董事会第二十次会议 决定召开公司 2026 年第一次临时股东会，具体内容如下。 1、会议召集人：公司董事会 2、会议召开的合法、合规性：本次股东会的召开符合《公司法》、《上市 公司股东会规则》等有关法律、行政法规、部门规章、规范性文件和本公司章程 的规定。 3、会议召开时间： （1）现场会议召开时间：2026 年 1 月 12 日（星期一）15:00 （2）网络投票时间：2026 年 1 月 12 日 其中，通过深圳证券交易所交易系统进行网络投票的时间：2026 年 1 月 12 日上午 9:15-9:25、9:30-11:30、下午 13:00-15:00；通过深圳证券交易所互联网投 票系统投票的具体时间为：2026 年 1 月 12 日 9:15-15:00 期间的任意时间。 4、现场会议地点：烟台市 ...

Group 1 - The core point of the article is that Ruikang Pharmaceutical announced the approval of a proposal to change its accounting firm during the 20th meeting of its fifth board of directors held on December 23 [2] Group 2 - The announcement was made public on December 24, indicating the company's ongoing governance and compliance activities [2] - The decision reflects the company's strategic moves in financial management and oversight [2]

Group 1 - The core point of the article is that Ruikang Pharmaceutical announced a board meeting to discuss the proposal to change the accounting firm and provided details on its revenue composition for the first half of 2025 [1] - Ruikang Pharmaceutical's revenue for the first half of 2025 is primarily derived from drug and medical device sales, which account for 98.42% of total revenue, while mobile healthcare contributes 0.67%, other sources 0.6%, and leasing 0.31% [1] - As of the report, Ruikang Pharmaceutical has a market capitalization of 5.3 billion yuan [2]

本议案以 8 票同意，0 票反对，0 票弃权的表决结果获得通过。 二、审议通过《关于提请召开公司 2026 年第一次临时股东会的议案》 证券代码：002589 证券简称：瑞康医药 公告编号：2025-057 瑞康医药集团股份有限公司 第五届董事会第二十次会议决议的公告 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）第五届董事会 第二十次会议通知于 2025 年 12 月 19 日以书面形式发出，2025 年 12 月 23 日上 午在烟台市芝罘区凤鸣路 103 号 13 号楼会议室以现场及通讯表决的方式召开。 会议由董事长韩旭先生主持，会议应出席董事 8 名，实际出席董事 8 名。本次会 议的召开符合《中华人民共和国公司法》等法律、法规和《公司章程》的规定。 本次会议经有效表决，形成如下决议： 一、审议通过《关于拟变更会计师事务所的议案》 为充分保障公司 2025 年度审计工作的顺利推进，按照《国有企业、上市公 司选聘会计师事务所管理办法》等有关规定，公司选聘 2025 年度审计机构事项 采用竞争性谈判的方式，经综合评估及审慎研究，公司拟聘深圳久安会计师事务 所（特殊普通合伙）为公司 2025 年 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-056 瑞康医药集团股份有限公司 关于拟变更会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述和重大遗漏。 特别提示： 1. 拟聘任的会计师事务所：深圳久安会计师事务所（特殊普通合伙）（以 下简称"深圳久安"）。 2. 原聘任的会计师事务所：中兴财光华会计师事务所（特殊普通合伙）（以 下简称"中兴财光华"） 3. 变更会计师事务所的原因：综合考虑公司业务发展及审计工作需求等情 况，为充分保障公司 2025 年度审计工作的顺利推进，按照《国有企业、上市公 司选聘会计师事务所管理办法》等有关规定，公司选聘 2025 年度审计机构事项 采用竞争性谈判的方式，经综合评估及审慎研究，从 3 家会计师事务所中选聘， 公司拟聘深圳久安为公司 2025 年度财务审计机构和内部控制审计机构。 4. 公司审计委员会、独立董事、董事会对本次变更会计师事务所事项无异 议。 本次变更事项尚需提交公司 2026 年第一次临时股东会审议。 一、拟变更会计师事务所的基本情况 （一）机构信息 1、基本信息 会计师事务所名称：深 ...

Core Viewpoint - The pharmaceutical commercial sector experienced a decline of 1.05% on December 16, with Ruikang Pharmaceutical leading the drop [1] Group 1: Market Performance - On the same day, the Shanghai Composite Index closed at 3824.81, down 1.11% [1] - The Shenzhen Component Index closed at 12914.67, down 1.51% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net outflow of 386 million yuan from main funds, while speculative funds had a net inflow of 157 million yuan [2] - Retail investors contributed a net inflow of 229 million yuan to the sector [2]

New Stock Issuance - The new stock "健信超导" (code: 787805) is issued at a price of 18.58[1] - The new stock "昂瑞微" (code: 688790) is listed at a price of 83.06[1] Rights Issues and Offers - "荃银高科" (code: 300087) has a tender offer period from December 4, 2025, to January 5, 2026[1] - "天普股份" (code: 605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] Delisting and Trading Alerts - "退市苏吴" (code: 600200) has 10 trading days remaining until the last trading day[1] - "ST广道" (code: 920680) has 12 trading days remaining until the last trading day[1] Stock Performance Alerts - "赛微电子" (code: 300456) has reported severe abnormal fluctuations[1] - "ST立方" (code: 300344) has also reported severe abnormal fluctuations[1]